Structure-activity relationships for 5-substituted 1- phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor

Journal of Medicinal Chemistry

Volumn 42, Issue 13, 1999, Pages 2373-2382

  Palmer, Brian D ^a   Kraker, Alan J ^b   Haitl, Brian G ^b   Panopoulos, Athanasia D ^b   Panek, Robert L ^b   Batley, Brian L ^b   Lu, Gina H ^b   Trumpp Kallmeyer, Susanne ^b   Showalter, H D Hollis ^b   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; CYCLIC AMP DEPENDENT PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; AORTA MEDIA; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG POTENCY; ENZYME INHIBITION; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; RESTENOSIS; STRUCTURE ACTIVITY RELATION; VASCULAR SMOOTH MUSCLE;

ADENOSINE TRIPHOSPHATE; ANIMALS; AORTA; BENZIMIDAZOLES; ENZYME INHIBITORS; HUMANS; LIGANDS; MODELS, MOLECULAR; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; RATS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033168447     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980658b     Document Type: Article

References (23)

1. Okamoto, S.; Indenk, M.; Setsuda, M.; Konishi, T.; Nakano, T. Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. Am. Heart J. 1992, 123, 1439-1444.
2. Kovalenko, M.; Gazit, A.; Bohmer, A.; Rorsman, C.; Ronnstrand, L.; Heldin, C. H.; Waltenberger, J.; Bohmer, F. D.; Levitzki, A. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 1994, 54, 6106-6114.
3. Plate, K. H.; Breier, G.; Risau, W. Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol. 1994, 4, 207-218.
4. Beck, L.; Damore, P. A. Vascular development - cellular and molecular regulation. FASEB J. 1997, 11, 365-373.
5. Fry, D. W. Recent advances in tyrosine kinase inhibitors. Ann. Rep. Med. Chem. 1996, 31, 151-160.
6. Maguire, M. P.; Sheets, K. R.; McVety, K.; Spada, A. P.; Zilberstein, A. A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J. Med. Chem. 1994, 37, 2129-2137.
7. Dolle, R. E.; Dunn, J. A.; Bobko, M.; Singh, B.; Kuster, J. E.; Baizman, E.; Harris, A. L.; Sawutz, D. G.; Miller, D.; Wang, S.; Faltynek, C. R.; Xie, W.; Sarup, J.; Bode, C. E.; Pagani, E. D.; Silver, P. J. 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular β-type platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 1994, 37, 2627-2629.
8. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, T.; Muller, M.; Regenass, U.; Lydon, N. B. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2558-2562.
9. Zimmermann, J.; Buchdunger, E.; Mett, H.; Meyer, T.; Lydon, N. B.; Traxler, P. Phenylaminopyrimidine (PAP) derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg. Med. Chem. Lett. 1996, 11, 1221-1226.
10. Palmer, B. D.; Smaill, J. B.; Boyd, M.; Boschelli, D. H.; Doherty, A. M.; Hamby, J. M.; Khatana, S. S.; Kramer, J. B.; Kraker, A. J.; Panek, R. L.; Lu, G. H.; Dahring, T. K; Winters, R. T.; Showalter, H. D. H.; Denny, W. A. Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J. Med. Chem. 1998, 41, 5457-5465.
11. Moody, C. J. Regioselective Claisen rearrangements in indoles. J. Chem. Soc., Perkin Trans. 1, 1984, 1333-1338.
12. Jacobson, P.; Jaenicke, M.; Meyer, F. Investigations on the reduction products of azo compounds. Ber. 1896, 29, 2680-2690.
13. Panek, R. L.; Lu, G. H.; Klutchko, S. R.; Batley, B. L.; Dahring, T. K.; Hamby, J. M.; Hallak, H.; Doherty, A. M.; Keiser, J. A. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J. Pharmacol. Exp. Ther. 1997, 283, 1433-1444.
14. Batley, B. L.; Doherty, A. M.; Hamby, J. M.; Lu, G. H.; Keller, P.; Dahring, T. K.; Hwang, O.; Crickard, K.; Panek, R. L. Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor. Life Sci. 1997, 62, 143-150.
15. Rewcastle, G. W.; Murray, D. K.; Elliott, W. L.; Fry, D. W.; Howard, C. T.; Nelson, J. M.; Roberts, B. J.; Vincent, P. W.; Showalter, H. D. H.; Winters, R. T.; Denny, W. A. Tyrosine Kinase Inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pynmidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors, J. Med. Chem. 1998, 41, 742-751.
16. Trumpp-Kallmeyer, S.; Rubin, J. R.; Humblett, C,; Hamby, J. M.; Showalter, H. D. H. Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidines. J. Med. Chem. 1998, 41, 1752-1763.
17. Palmer, B. D.; Trumpp-Kallmeyer, S.; Fry, D. W.; Nelson, J. M.; Showalter, H. D. H.; Denny, W. A. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as EGFR inhibitors: synthesis, biological evaluation and modelling of the mode of binding. J. Med. Chem. 1997, 40, 1519-1529.
18. LOOK Molecular Applications Group, Suite T, 445 Sherman Ave., Palo Alto, CA 94306.
19. Hey, D. H.; Lobo, L. C. The Aporphine series. Part 1. Developments of the Bischler-Napieralski-Pachorr synthetic method. The synthesis of (±)-isoBulbocaprine and (±)-actinodaphnine methyl ether. J. Chem. Soc. 1954, 2246-2256.
20. Peters, W.; Piotrowska, H.; Serafin, B.; Urbanski, T. Antimalarial compounds. XTV. New derivatives of 2-bromo-N,N-bis-(diethylaminoethyl)-4,5-dimethoxyaniline. Pol. J. Pharmacol. Pharm. 1975, 27, 289-295. Chem. Abstr. 1975, 83, 172557s.
21. Peters, W.; Piotrowska, H.; Serafin, B.; Urbanski, T. Antimalarial compounds. XTV. New derivatives of 2-bromo-N,N-bis-(diethylaminoethyl)-4,5-dimethoxyaniline. Pol. J. Pharmacol. Pharm. 1975, 27, 289-295. Chem. Abstr. 1975, 83, 172557s.
22. Dadswell, H. E.; Kenner, J. Influence of nitro groups on the reactivity of substituents in the benzene nucleus. IX. 2,3- and 2,5-Dinitro-4-methoxytoluenes. J. Chem. Soc. 1927, 580-588.
23. Yarden, Y.; Escobedo, J. A., Kuang, W. J., Yang-Feng, T. L.; Daniel, T. O.; Tremble, P. M.; Chen, E. Y.; Ando, M. E.; Harkins, R. N.; Francke, U.; Fried, V. A.; Ullrich. A.; Williams, L. T. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature 1986, 323, 226-232.